Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

<ul>
<li>We currently see one change each for the ASX20 and ASX100 indices, 4 changes for the <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200</a> and 10 adds/ 6 deletes for the ASX300 Index in March.</li>
<li>There could be an addition to the <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200 (AS51 INDEX)</a> in January following <a href="https://www.smartkarma.com/entities/pendal-group-ltd" target="_blank" data-smartkarma-citation="entities:15795:1" rel="noopener">Pendal Group (PDL AU)</a>'s acquisition by <a href="https://www.smartkarma.com/entities/perpetual-ltd" target="_blank" data-smartkarma-citation="entities:599:1" rel="noopener">Perpetual Ltd (PPT AU)</a>.</li>
<li>
<a href="https://www.smartkarma.com/entities/pexa-group-ltd" target="_blank" data-smartkarma-citation="entities:34716:1" rel="noopener">PEXA Group (PXA AU)</a> is a potential inclusion to the <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200 (AS51 INDEX)</a> if <a href="https://www.smartkarma.com/entities/link-administration-holdings-ltd" target="_blank" data-smartkarma-citation="entities:970:1" rel="noopener">Link Administration (LNK AU)</a>'s in-specie distribution of PEXA shares to its shareholders is approved.</li>
</ul>


We currently see one change each for the ASX20 and ASX100 indices, 4 changes for the S&amp;P/ASX 200 and 10 adds/ 6 deletes for the ASX300 Index in March.
There could be an addition to the S&amp;P/ASX 200 (AS51 INDEX) in January following Pendal Group (PDL AU)'s acquisition by Perpetual Ltd (PPT AU).

PEXA Group (PXA AU) is a potential inclusion to the S&amp;P/ASX 200 (AS51 INDEX) if Link Administration (LNK AU)'s in-specie distribution of PEXA shares to its shareholders is approved.


S&P/​​​​​ASX Index Rebalance Preview: A Busy March (Maybe January and February Too)

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Dec 2nd (reported today) which has an aggregated short interest worth USD17.4bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in IGO, Pilbara Mineral, Seek, Carsales.com, Allkem, Woodside Energy, Domino's Pizza, Westfarmers, Evolution Mining.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Dec 2nd (reported today) which has an aggregated short interest worth USD17.4bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in IGO, Pilbara Mineral, Seek, Carsales.com, Allkem, Woodside Energy, Domino's Pizza, Westfarmers, Evolution Mining.


ASX Short Interest Weekly (Dec 2nd): IGO, Pilbara Mineral, Seek, Carsales.com, Allkem

Pan-Asia Index Flows & Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Pan-Asia Index Flows & Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

<ul>
<li>The index changes for the S&amp;P ASX Index family for the December 2022 Rebalance were announced after the close on Friday 2nd December 2022.</li>
<li>There will be one ADD/DEL for the ASX 50 index and one ADD/DEL for the ASX 200 index.</li>
<li>In this insight, we take a closer look at our expectations for index flows and potential trading ideas.</li>
</ul>


The index changes for the S&amp;P ASX Index family for the December 2022 Rebalance were announced after the close on Friday 2nd December 2022.
There will be one ADD/DEL for the ASX 50 index and one ADD/DEL for the ASX 200 index.
In this insight, we take a closer look at our expectations for index flows and potential trading ideas.


S&P ASX Dec 22 Rebalance: MND Is the Top Pick

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>In terms of geography, Japan is still our top pick, primarily due to attractive multiple, favorable Fx, and low leverage. Despite macroeconomic headwinds, Australia biotech is another area of interest.</li>
<li>Among our four top picks, Gland Pharma reported year-over-year decline across all parameters during Q2FY23 due to supply woes. Near-term outlook is uncertain.</li>
<li>Apollo Hospitals reported strong quarterly performance, with all operating parameters improving year-over-year. Olympus remained a prime beneficiary of weak yen, while Samsung Biologics’ robust order book entail visibility.</li>
</ul>


In terms of geography, Japan is still our top pick, primarily due to attractive multiple, favorable Fx, and low leverage. Despite macroeconomic headwinds, Australia biotech is another area of interest.
Among our four top picks, Gland Pharma reported year-over-year decline across all parameters during Q2FY23 due to supply woes. Near-term outlook is uncertain.
Apollo Hospitals reported strong quarterly performance, with all operating parameters improving year-over-year. Olympus remained a prime beneficiary of weak yen, while Samsung Biologics’ robust order book entail visibility.


APAC Healthcare Series (Part 4)- Japan Continues to Be in a Sweet Spot; Top Picks Quarterly Update

<ul>
<li>In this insight, we take a look at the potential index changes for S&amp;P ASX 200, 100, 50, and 20 in the run up to the December 2022 Rebalance.</li>
<li>The 6-month reference period for the December 2022 Rebalance is now complete.</li>
<li>I do not see any changes for ASX 20 or ASX 100. I see one ADD/DEL for ASX 50 and three ADDs/DELs for ASX 200.</li>
</ul>


In this insight, we take a look at the potential index changes for S&amp;P ASX 200, 100, 50, and 20 in the run up to the December 2022 Rebalance.
The 6-month reference period for the December 2022 Rebalance is now complete.
I do not see any changes for ASX 20 or ASX 100. I see one ADD/DEL for ASX 50 and three ADDs/DELs for ASX 200.


S&P/​​​​​​​​ASX Quiddity Final Expectations Dec 22: Mostly Mining Companies, Avoid Short Buildup!

Australia

PolyNovo Limited is a biotechnology company. The Company has a portfolio of biodegradeable polymers that have potential for application across numerous medical fields.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

PolyNovo Ltd (PNV AU)

S&P/ASX Index Rebalance Preview: A Busy March (Maybe January and February Too)

There could be an adhoc ASX200 inclusion in Jan. Then there could be 1 change each for the ASX20 and ASX100 indices, 4 changes for the ASX200...

Brian Freitas

ASX Short Interest Weekly (Dec 2nd): IGO, Pilbara Mineral, Seek, Carsales.com, Allkem

We analyzed ASX short interest report for the past week and highlight short interest changes in IGO, Pilbara Mineral, Seek, Carsales.com, Allkem,...

Ke Yan, CFA, FRM

S&P ASX Dec 22 Rebalance: MND Is the Top Pick

ASX 200 ADD Monadelphous seems to be the most interesting name. There could be ~12 days of volume to buy and historically ASX 200 ADDs have...

Janaghan Jeyakumar, CFA

APAC Healthcare Series (Part 4)- Japan Continues to Be in a Sweet Spot; Top Picks Quarterly Update

Japan healthcare companies with high export revenue, continue to benefit from favorable Fx. Three of our top picks reported strong quarterly...

Tina Banerjee

S&P/ASX Quiddity Final Expectations Dec 22: Mostly Mining Companies, Avoid Short Buildup!

Among the Expected DELs, St Barbara and Smartgroup have significant short buildup. The ASX 50 Expected ADDs/DELs are fairly low-impact names. But...

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

S&P/​​​​​ASX Index Rebalance Preview: A Busy March (Maybe January and February Too)

There could be an adhoc ASX200 inclusion in Jan. Then there could be 1 change each for the ASX20 and ASX100 indices, 4 changes for the ASX200...

Brian Freitas

ASX Short Interest Weekly (Dec 2nd): IGO, Pilbara Mineral, Seek, Carsales.com, Allkem

We analyzed ASX short interest report for the past week and highlight short interest changes in IGO, Pilbara Mineral, Seek, Carsales.com, Allkem,...

Ke Yan, CFA, FRM

S&P ASX Dec 22 Rebalance: MND Is the Top Pick

ASX 200 ADD Monadelphous seems to be the most interesting name. There could be ~12 days of volume to buy and historically ASX 200 ADDs have...

Janaghan Jeyakumar, CFA

APAC Healthcare Series (Part 4)- Japan Continues to Be in a Sweet Spot; Top Picks Quarterly Update

Japan healthcare companies with high export revenue, continue to benefit from favorable Fx. Three of our top picks reported strong quarterly...

Tina Banerjee

S&P/​​​​​​​​ASX Quiddity Final Expectations Dec 22: Mostly Mining Companies, Avoid Short Buildup!

Among the Expected DELs, St Barbara and Smartgroup have significant short buildup. The ASX 50 Expected ADDs/DELs are fairly low-impact names. But...

Janaghan Jeyakumar, CFA

S&P/ASX Index Rebalance Preview: A Busy March (Maybe January and February Too)

S&P/ASX Quiddity Final Expectations Dec 22: Mostly Mining Companies, Avoid Short Buildup!